Astrazeneca (AZN) Depreciation & Amortization (CF) (2009 - 2026)

Astrazeneca (AZN) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $1.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 6.39% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $5.8 billion (down 13.43% YoY), while the FY2025 annual figure was $5.7 billion, down 14.28% from the prior year.
• Depreciation & Amortization (CF) came in at $1.4 billion for Q1 2026 at Astrazeneca, down from $1.5 billion in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $4.1 billion in Q4 2023, with the low at $1.3 billion in Q1 2024.
• Average Depreciation & Amortization (CF) over 5 years is $1.8 billion, with a median of $1.4 billion recorded in 2025.
• Across the five-year window, Depreciation & Amortization (CF) jumped 107.87% in 2022 and sank 42.44% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $4.0 billion in 2022, then increased by 1.5% to $4.1 billion in 2023, then slumped by 42.44% to $2.3 billion in 2024, then sank by 35.34% to $1.5 billion in 2025, then retreated by 9.6% to $1.4 billion in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.4 billion, $1.5 billion, and $1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.